BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 26879359)

  • 21. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies.
    Biondo MI; Germano V; Pietrosanti M; Canzoni M; Marignani M; Stroffolini T; Salemi S; D'Amelio R
    Eur J Intern Med; 2014 Jun; 25(5):482-4. PubMed ID: 24495663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.
    Talotta R; Atzeni F; Sarzi Puttini P
    BMC Pharmacol Toxicol; 2016 Apr; 17():17. PubMed ID: 27098382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients.
    Lee J; Park JY; Huh KH; Kim BS; Kim MS; Kim SI; Ahn SH; Kim YS
    Nephrol Dial Transplant; 2017 Apr; 32(4):722-729. PubMed ID: 28339910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
    Watanabe T; Fukae J; Fukaya S; Sawamukai N; Isobe M; Matsuhashi M; Shimizu M; Akikawa K; Tanimura K; Atsumi T; Koike T
    Int J Rheum Dis; 2019 Apr; 22(4):574-582. PubMed ID: 30338649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib.
    Wang ST; Tseng CW; Hsu CW; Tung CH; Huang KY; Lu MC; Lai NS
    Int J Rheum Dis; 2021 Nov; 24(11):1362-1369. PubMed ID: 34506078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Biologics Treatment.
    Chen MH; Chen MH; Liu CY; Tsai CY; Huang DF; Lin HY; Lee MH; Huang YH
    J Infect Dis; 2017 Feb; 215(4):566-573. PubMed ID: 28011918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.
    Chen LF; Mo YQ; Jing J; Ma JD; Zheng DH; Dai L
    Int J Rheum Dis; 2017 Jul; 20(7):859-869. PubMed ID: 28160426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.
    Matsui T; Kang JH; Nojima M; Tomonari A; Aoki H; Yamazaki H; Yane K; Tsuji K; Andoh S; Andoh S; Sakai H; Maemori M; Maguchi H; Tanaka Y
    J Med Virol; 2013 Nov; 85(11):1900-6. PubMed ID: 23926082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short article: Safety of targeted prophylaxis strategy in patients with resolved hepatitis B virus infection receiving rituximab for immune-mediated diseases.
    Spinicci M; Emmi G; Dies L; Barilaro A; Vitiello G; Mencarini J; Cavallo A; Bartoloni A; Bartalesi F
    Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):756-760. PubMed ID: 29649073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment.
    Kuo MH; Tseng CW; Lu MC; Tung CH; Tseng KC; Huang KY; Lee CH; Lai NS
    Dig Dis Sci; 2021 Nov; 66(11):4026-4034. PubMed ID: 33387124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HBV reactivation in HBsAg-/HBcAb+ rheumatoid arthritis patients receiving biologic/targeted synthetic DMARDs.
    Kuo MH; Tseng CW; Ko PH; Wang ST; Lu MC; Tung CH; Tseng KC; Huang KY; Lee CH; Lai NS
    Liver Int; 2024 Feb; 44(2):497-507. PubMed ID: 38010984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation.
    Chen YM; Chen HH; Huang WN; Chen YH; Hsieh TY; Yang SS; Lan JL; Chen DY
    Int J Rheum Dis; 2019 Jun; 22(6):1145-1151. PubMed ID: 31117160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
    Nakamura J; Nagashima T; Nagatani K; Yoshio T; Iwamoto M; Minota S
    Int J Rheum Dis; 2016 May; 19(5):470-5. PubMed ID: 24698305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
    Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
    J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.
    Yang HC; Tsou HH; Pei SN; Chang CS; Chen JH; Yao M; Lin SJ; Lin J; Yuan Q; Xia N; Liu TW; Chen PJ; Cheng AL; Hsu C;
    J Hepatol; 2018 Aug; 69(2):286-292. PubMed ID: 29551710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
    Lee YH; Bae SC; Song GG
    Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs.
    Mori S
    Mod Rheumatol; 2011 Dec; 21(6):621-7. PubMed ID: 21528424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.
    Yoo JJ; Cho EJ; Cho YY; Lee M; Lee DH; Cho Y; Lee JH; Yu SJ; Yoon SS; Yoon JH; Kim YJ
    Liver Int; 2015 Dec; 35(12):2530-6. PubMed ID: 26053357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvements in hepatitis B virus screening before rituximab therapy: A community-based, safety-net hospital experience.
    Junus K; Aguilar M; Patel P; Irwin D; Yee S; Liu B; Bhuket T; Wong RJ
    Cancer; 2017 Feb; 123(4):650-656. PubMed ID: 27696389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy.
    Fidan S; Capkın E; Arıca DA; Durak S; Okatan IE
    Int J Rheum Dis; 2021 Feb; 24(2):254-259. PubMed ID: 33244900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.